Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$15.47 USD
+0.16 (1.05%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Verona Pharma PLC American Depositary Share falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 40 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 40 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 76 | 113 | 74 | 52 |
Income After Depreciation & Amortization | -68 | -76 | -73 | -74 | -52 |
Non-Operating Income | 16 | 8 | 18 | 9 | 3 |
Interest Expense | 2 | 1 | 0 | 0 | 1 |
Pretax Income | -54 | -68 | -56 | -65 | -50 |
Income Taxes | 0 | 0 | 0 | 0 | -9 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -54 | -69 | -56 | -65 | -41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -54 | -69 | -56 | -65 | -41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -67 | -75 | -73 | -74 | -52 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -68 | -76 | -73 | -74 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 79.27 | 66.13 | 59.15 | 32.87 | 13.17 |
Diluted EPS Before Non-Recurring Items | -0.72 | -1.04 | -0.96 | -2.57 | -3.10 |
Diluted Net EPS (GAAP) | -0.69 | -1.04 | -0.96 | -2.00 | -3.10 |
Fiscal Year end for Verona Pharma PLC American Depositary Share falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.09 | 16.31 | 9.97 | 22.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -19.09 | -16.31 | -9.97 | -22.20 |
Non-Operating Income | NA | 5.53 | 2.07 | 2.21 | 5.92 |
Interest Expense | NA | 0.62 | 0.40 | 0.74 | 0.29 |
Pretax Income | NA | -14.19 | -14.64 | -8.50 | -16.57 |
Income Taxes | NA | -0.05 | 0.04 | 0.31 | 0.17 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.13 | -14.69 | -8.81 | -16.74 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -14.13 | -14.69 | -8.81 | -16.74 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 80.27 | 79.78 | 79.31 | 77.68 |
Diluted EPS Before Non-Recurring Items | NA | -0.16 | -0.18 | -0.11 | -0.24 |
Diluted Net EPS (GAAP) | NA | -0.18 | -0.18 | -0.08 | -0.24 |